首页 奥洛兹美疗法(usHALO)-基本信息

奥洛兹美疗法(usHALO)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:48.65

最高价:50.49

成交量:1018034.0

昨收价:48.84

最低价:48.65

最新价:49.3

行情图标
概要信息

中文名称:奥洛兹美疗法


英文名称:Halozyme Therapeutics


行业:医疗


简介:Halozyme Therapeutics, Inc.是一家生物制药公司,成立于1998年


电话:1-858-7948889


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Halozyme Therapeutics是一家生物制药公司, 其人类酶被用于促进注射药物和流体的输送,增强效力和其它药物的吸收,亦可用于临床改变异常组织结构。奥洛兹美医疗的产品是基于其专有技术的“人重组透明质酸酶(rHuPH20)”Enhanze技术平台开发,使可注射的生物制剂(包括:单克隆抗体和其它治疗分子,以及小分子和流体)可以通过皮下输送。公司产品包括: Hylenex recombinant——一种rHuPH20制剂,以方便实现水化皮下输液;提高分散性和其它注射药物的吸收;皮下尿路造影;提高不透射线剂的吸收。 PEGPH20——目前处于转移性胰腺癌的治疗的II期临床试验阶段,以及非小细胞肺癌治疗的I期临床试验阶段。目前,奥洛兹美医疗已与多个知名医药公司达成合作关系来开发其ENHANZE™药物输送平台,其中包括:F. Hoffmann-La Roche, Ltd.、Hoffmann-La Roche, Inc.、Baxter Healthcare Corporation、Pfizer Inc.、Janssen Biotech, Inc.、内克塔治疗(Nektar Therapeutics)、Eisai Co., Ltd.、AbbVie 和 Lilly等。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-14 Stelzer (Laurie D) Chief Financial Officer Buy 6875 --
2019-06-14 Stelzer (Laurie D) Chief Financial Officer Sell 3408 15.73
2019-05-31 Chondros (Dimitrios) Officer Sell 706 14.75
2019-05-31 Chondros (Dimitrios) Officer Buy 2043 --
2019-05-01 Bizzari (Jean-Pierre) Director Buy 12173 --
2019-05-01 Kelley (Kenneth J) Director Buy 12173 --
2019-05-01 Henderson (Jeffrey William) Director Buy 12173 --
2019-05-01 Daly (James M.) Director Buy 12173 --
2019-05-01 Connaughton (Bernadette M.) Director Buy 12173 --
2019-05-01 Matsui (Connie L) Director Buy 12173 --
2019-05-01 Posard (Matthew L) Director Buy 12173 --
2019-04-12 Leonhardt (Harry J. Esq.) General Counsel Buy 6875 --
2019-04-12 Leonhardt (Harry J. Esq.) General Counsel Sell 2377 16.54
2019-02-21 Torley (Helen I) Chief Executive Officer Sell 19511 16.81
2019-02-21 Torley (Helen I) Chief Executive Officer Buy 39354 --
2019-02-21 Stelzer (Laurie D) Chief Financial Officer Buy 11392 --
2019-02-21 Stelzer (Laurie D) Chief Financial Officer Sell 3939 16.81
2019-02-21 Chondros (Dimitrios) Officer Buy 3884 --
2019-02-21 Chondros (Dimitrios) Officer Sell 1343 16.81
2019-02-21 Leonhardt (Harry J. Esq.) General Counsel Sell 3939 16.81
2019-02-21 Leonhardt (Harry J. Esq.) General Counsel Buy 11392 --
2019-02-13 Chondros (Dimitrios) Officer Buy 6790 --
2019-02-13 Chondros (Dimitrios) Officer Sell 2322 16.54
2019-02-13 Leonhardt (Harry J. Esq.) General Counsel Sell 2700 16.54
2019-02-13 Torley (Helen I) Chief Executive Officer Sell 14244 16.54

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
First Eagle Investment Management, LLC 2128275 1.45% -- -- 2019-07-31
State Street Corporation 3953883 2.72% -153618 -3.74% 2019-03-31
BlackRock Fund Advisors 6104254 4.17% 78396 1.30% 2019-07-31
Iridian Asset Management LLC 7010066 4.82% -2017098 -22.34% 2019-03-31
Bellevue Asset Management AG 8247860 5.64% -139000 -1.66% 2019-07-31
BB Biotech AG 8322860 5.72% -- -- 2019-03-31
BlackRock Inc 11695148 8.04% -60972 -0.52% 2019-03-31
Vanguard Group Inc 13518190 9.29% 46272 0.34% 2019-03-31
Third Security, LLC 14092771 9.69% -- -- 2019-03-31
Pictet Asset Management Ltd 3901571 2.68% 185763 5.00% 2019-03-31
Pictet Asset Management SA (Junked) 3901571 2.68% 185763 5.00% 2019-03-31
Vanguard Investments Australia Ltd 3697144 2.53% -11214 -0.30% 2019-07-31
J.P. Morgan Investment Management, Inc. 2134283 1.46% 64706 3.13% 2019-07-31
Arnhold & S. Bleichroeder Advisers, LLC 2128275 1.46% -2500 -0.12% 2019-03-31
Northern Trust Investments Inc 2528610 1.73% 23839 0.95% 2019-07-31
Fidelity Management and Research Company 2683787 1.84% 127379 4.98% 2019-03-31
FMR Inc 2685575 1.85% 127379 4.98% 2019-03-31
Fidelity SelectCo, LLC 2789296 1.91% -40300 -1.42% 2019-07-31
Snyder Capital Management LP 2826601 1.94% -7158 -0.25% 2019-03-31
Thrivent Financial For Lutherans 3669830 2.52% 107325 3.01% 2019-03-31
Amvescap Plc. 4214114 2.90% 34661 0.83% 2018-12-31
BlackRock Asset Management Canada Ltd 2865794 1.97% -672 -0.02% 2019-05-31
Geode Capital Management, LLC 3041314 2.09% 1597410 110.63% 2018-12-31
JPMorgan Chase & Co 3601604 2.48% 400008 12.49% 2018-09-30
Artisan Partners Limited Partnership 2039215 1.41% -122657 -5.67% 2018-12-31
MSD Partners, L.P. 2245000 1.55% -- -- 2018-09-30
Invesco Advisers, Inc 3716982 2.57% -40044 -1.07% 2018-06-30
BlackRock Institutional Trust Company NA 3845143 2.66% 42659 1.12% 2018-06-30
State Street Corp 4575701 3.17% -423017 -8.46% 2018-06-30
Pictet Asset Management SA 2640762 1.83% 172434 6.99% 2018-06-30
Northern Trust Investments N A 1850077 1.28% 192497 11.61% 2018-06-30
J P Morgan Asset Management (UK) Ltd 1750028 1.21% 26012 1.51% 2018-06-30
J.P. Morgan Investment Management Inc 1340096 0.93% 196097 17.14% 2018-06-30
Baker Bros Advisors LP 1283929 0.89% -297495 -18.81% 2018-06-30
Quantitative Management Associates LLC 1257520 0.87% 403604 47.27% 2018-03-31
Millennium Management LLC 1373247 0.95% -101896 -6.91% 2018-03-31
SENZAR ASSET MANAGEMENT, LLC 3830190 2.69% -257074 -6.29% 2017-09-30
Sectoral Asset Management Inc 1227931 0.86% -637 -0.05% 2017-09-30
OppenheimerFunds Inc 1002315 0.70% -178 -0.02% 2017-12-31
BlackRock Advisors LLC 1029457 0.72% -26420 -2.50% 2017-12-31
Government Pension Fund of Norway - Global 1005761 0.88% 330277 48.89% 2013-12-31
ING Investment Management LLC 1705777 1.32% -170095 -9.07% 2016-09-30
Franklin Advisers Inc 2205769 1.70% 7140 0.32% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Invesco Oppenheimer Global Opports Fund 1000000 0.68% -- -- 2019-06-30
Invesco Small Cap Growth Fund 1805342 1.23% 101474 5.96% 2019-06-30
JPMorgan Small Cap Growth Fund 1806883 1.23% 51631 2.94% 2019-06-30
Vanguard Small Cap Growth Index Fund 1918834 1.31% -10906 -0.57% 2019-06-30
First Eagle Fund of America 2128275 1.45% -- -- 2019-05-31
Fidelity 2439407 1.67% -40300 -1.63% 2019-06-30
iShares Russell 2000 ETF 3170244 2.17% 41165 1.32% 2019-07-30
Vanguard Small Cap Index 3320785 2.27% -105659 -3.08% 2019-06-30
Vanguard Total Stock Market Index Fund 3666181 2.51% 780 0.02% 2019-06-30
Vanguard Extended Market Index Fund 1755724 1.20% 1798 0.10% 2019-06-30
SPDR 1542717 1.05% 23925 1.58% 2019-07-31
iShares Nasdaq Biotechnology ETF 1436411 0.98% 16204 1.14% 2019-07-30
iShares Russell 2000 Growth ETF 1313643 0.90% 21016 1.63% 2019-07-30
Nomura World Genome Tech Open Mother 1258800 0.86% 342900 37.44% 2018-11-19
Thrivent Mid Cap Stock Fund 1246927 0.85% 14600 1.18% 2019-05-31
Artisan Small Cap Fund 1219655 0.83% -60230 -4.71% 2019-06-30
JNL/Invesco Small Cap Growth Fund 1188203 0.81% -13525 -1.13% 2019-03-31
Thrivent Mid Cap Stock Portfolio 1070386 0.73% -- -- 2019-05-31
JPM Global Healthcare Fund 1060053 0.72% 311736 41.66% 2019-06-30
Pictet-Biotech 1386606 0.95% 46722 3.49% 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 2575603 1.77% -4320 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 3418305 2.35% 10184 0.30% 2019-04-30
Oppenheimer Global Opportunities Fund 1000000 0.69% -- -- 2019-01-31
FPIL Optus JF Glb Life Sciences Theme 1062345 0.73% 23012 2.21% 2019-01-31
BrighthouseI Invesco Small Cap Gr Port 594551 0.41% 6779 1.15% 2018-12-31
JPM Global Healthcare Fund UL 1039333 0.72% -- -- 2018-12-31
Dreyfus/The Boston Co Sm/Md Cp Gr Fd 625891 0.43% -77693 -11.04% 2018-10-31
JPMorgan Small Cap Growth A 1103034 0.76% 83336 8.17% 2018-07-31
Met Invt Ser Invesco Small Cap Gr A 616337 0.43% -81773 -11.71% 2018-06-30
Fidelity Spartan 619155 0.43% 21861 3.66% 2018-07-31
Vanguard Total Stock Mkt Idx 3038929 2.11% 3680 0.12% 2018-07-31
Vanguard Extended Market Idx Inv 1768082 1.23% 7800 0.44% 2018-07-31
Vanguard Small Cap Growth Index Inv 1747895 1.21% 19469 1.13% 2018-07-31
Invesco Small Cap Growth A 1701178 1.18% 9397 0.56% 2018-06-30
iShares Nasdaq Biotechnology 1632156 1.06% -3108 -0.19% 2018-09-12
iShares Russell 2000 Growth 1218787 0.79% -1175 -0.10% 2018-09-12
JNL/Invesco Small Cap Growth B 1186411 0.82% 38270 3.33% 2018-06-30
Oppenheimer Global Opportunities A 1000000 0.69% -- -- 2018-07-31
First Eagle Fund of America Y 2124563 1.47% -529600 -19.95% 2018-06-30
Dreyfus/The Boston Co Sm/Md Cp Gr I 703584 0.49% -- -- 2018-07-31
BlackRock Health Sciences Opps Inv A 757100 0.52% -- -- 2018-07-31
Thrivent Ser Mid Cap Stock 959736 0.67% -- -- 2018-06-30
Thrivent Mid Cap Stock A 1032277 0.72% -- -- 2018-06-30
Artisan Small Cap Investor 1056760 0.73% 36680 3.60% 2018-06-30
Vanguard Market Neutral I 453279 0.32% -- -- 2018-03-31
Fidelity Advisor 544131 0.38% -- -- 2018-06-30
Delaware Healthcare A 500000 0.35% -- -- 2018-05-31
AST Prudential Growth Allocation Port 506200 0.35% 100500 24.77% 2018-01-31
TIAA-CREF Small-Cap Equity Instl 539000 0.42% -- -- 2016-12-31
PowerShares Dynamic Biotech & Genome ETF 513032 0.42% -- -- 2017-02-08
Fidelity® Select Biotechnology Portfolio 4326439 3.40% 277536 6.80% 2015-10-31
Fidelity Advisor® Biotechnology Fund 979927 0.80% 90222 10.10% 2015-10-31
JPM Global Healthcare 997005 0.80% 245087 32.60% 2015-09-30
Oppenheimer Global Opportunities 1000000 0.80% -- -- 2015-09-30
Iridian U.S. Equity Fund 1121655 0.90% 27750 2.50% 2015-10-31
SPDR® S&P Biotech ETF 1360624 1.20% 4274 0.30% 2015-11-27
iShares Russell 2000 (AU) 1734234 1.60% -1062 -0.10% 2015-11-27

Randal J. Kirk Mr. Randal J. Kirk is Chairman & Chief Executive Officer at Intrexon Corp., Chairman at Harvest Pharmaceuticals, Inc., CEO, Senior Managing Director & Founder at Third Security LLC and Chairman, President & Chief Executive Officer at New River Pharmaceuticals, Inc. He is on the Board of Directors at ZIOPHARM Oncology, Inc. and Halozyme Therapeutics, Inc. Mr. Kirk was previously employed as Chairman by Cyntellect, Inc., Chairman by Clinical Data, Inc., Chairman by ECDS LLC, Co-Founder by KP Pharmaceuticals, Inc., Chairman by General Injectables & Vaccines, Inc., Chairman by Pinnacle Pharmaceuticals LLC, and Chairman by SouthernSun Asset Management LLC. He also served on the board at Howe & Rusling, Inc., Scios, Inc., Radford University Foundation, Inc. and Talkflow Systems LLC. He received his undergraduate degree from Radford University and a graduate degree from the University of Virginia.
Connie L. Matsui Presently, Connie L. Matsui holds the position of Chairman at Halozyme Therapeutics, Inc., Chairman of Sutro Biopharma, Inc. and Chairman for Artelo Biosciences, Inc. Ms. Matsui is also Secretary & Vice Chairman-Governors Board at The San Diego Foundation. In her past career she held the position of Executive VP-Knowledge & Innovation Networks at Biogen, Inc. Executive Vice President for Biogen Idec New Ventures, Inc. and Senior Vice President for IDEC Pharmaceuticals Corp. (both are subsidiaries of Biogen, Inc.) and National President at Girl Scouts of the USA. Ms. Matsui received an undergraduate degree and an MBA from Stanford University.
David A. Ramsay Founder of Bonti, Inc., David A. Ramsay occupies the position of Chief Financial Officer at Bonti, Inc. and Chief Financial Officer of Halozyme Therapeutics, Inc. Mr. Ramsay is also on the board of F1 Oncology, Inc. and Savara, Inc. In the past he occupied the position of Chief Financial Officer & Vice President at Halozyme Therapeutics, Inc., Chief Financial Officer & Vice President at Lathian Systems, Inc., Treasurer & Vice President for Valeant Pharmaceuticals International Corp., Auditor of Deloitte & Touche LLP and Vice President & Controller of Security Pacific Asian Bank. Mr. Ramsay received an undergraduate degree from the University of California, Berkeley and an MBA from The Wharton School of the University of Pennsylvania.
Jeffrey William Henderson Jeffrey William Henderson occupies the position of Non-Executive Chairman of QUALCOMM, Inc. He is also on the board of 7 other companies. Mr. Henderson previously occupied the position of Chief Financial Officer of Cardinal Health, Inc., Vice President & Controller of Eli Lilly & Co. and President & General Manager at Eli Lilly Canada, Inc. (a subsidiary of Eli Lilly & Co.), Chief Financial Officer at IBC Vehicles Ltd. and Principal at General Motors Corp. Mr. Henderson received an undergraduate degree from Kettering University and an MBA from Harvard Business School.
Helen I. Torley Helen I. Torley occupies the position of President, Chief Executive Officer & Director at Halozyme Therapeutics, Inc. Dr. Torley is also on the board of Quest Diagnostics, Inc. and Member of The Royal College of Physicians and Director & Member-Health Section Governing Board at Biotechnology Innovation Organization. In her past career she was Vice President & GM-Bone Health Unit at Amgen, Inc. and Chief Commercial Officer & Executive VP for Onyx Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.), Vice President-Medical Affairs for Novartis, Inc., Vice President-Medical Affairs of Sandoz SA and Vice President-Cardiovascular & Metabolic Sales at Bristol-Myers Squibb World Wide Medicines Group. She received an undergraduate degree from the University of Glasgow.
Matthew L. Posard Matthew L. Posard is on the board of Halozyme Therapeutics, Inc., DermTech, Inc. and Fabric Genomics, Inc. In the past Mr. Posard occupied the position of President & Chief Commercial Officer at GenePeeks, Inc., Chief Commercial Officer & Executive VP for TrovaGene, Inc., Senior VP, GM-New & Emerging Market Opportunities at Illumina, Inc., Senior Manager-Strategic Marketing at Gen-Probe, Inc. and Regional Director-Sales at Alere San Diego, Inc. He received an undergraduate degree from the University of California San Diego.
Harry J. Leonhardt Presently, Harry J. Leonhardt occupies the position of Secretary, Senior VP & General Counsel at Halozyme Therapeutics, Inc. He is also on the board of BIOCOM. Mr. Leonhardt previously was Secretary, Senior Vice President & General Counsel at Ngen, Inc., Chief Litigation Counsel at Allergan, Inc., Attorney at Lyon & Lyon, Inc., Secretary, Executive VP & General Counsel of Genoptix, Inc., Secretary, Senior VP-Legal & Compliance at Amylin Pharmaceuticals, Inc. and Secretary, Senior Vice President & General Counsel at Senomyx, Inc. Harry J. Leonhardt received an undergraduate degree from the University of the Sciences in Philadelphia and a graduate degree from the University of Southern California.
Homa Yeganegi Homa Yeganegi is Vice President-Global Scientific & Medical Affairs at Halozyme Therapeutics, Inc. Ms. Yeganegi received an undergraduate degree from the University of Tehran and a graduate degree from The University of Western Australia.
Kenneth J. Kelley Kenneth J. Kelley is a businessperson who founded IntraBiotics Pharmaceuticals, Inc. and PaxVax, Inc. and who has been the head of 5 different companies. He is on the board of Halozyme Therapeutics, Inc. (former Chairman), Albert B. Sabin Vaccine Institute, Inc. and Meissa Vaccines, Inc. and Managing Director at K2 BioVentures LLC. Mr. Kelley previously was Chairman of Fluxion Biosciences, Inc., Director at Solus Biosystems, Inc., Associate for Institutional Venture Partners, Consultant at McKinsey & Co., Inc., General Partner of Latterell Venture Partners, Director at PaxVax, Inc., Chairman & Chief Executive Officer for IntraBiotics Pharmaceuticals, Inc. and Scientist at Integrated Genetics, Inc. He received an undergraduate degree from Harvard University and an MBA from Stanford University.
William J. Fallon William J. Fallon holds the position of SVP-CMC Operations & Strategic Alliances at Halozyme Therapeutics, Inc. He previously occupied the position of Vice President-US Manufacturing Operations at Ares-Serono Group, President & Chief Executive Officer of Cytovance Biologics, Inc., Vice President of Technical Operations at Genzyme Corp., Vice President of Manufacturing at Transkaryotic Therapies, Inc., Vice President-Technical Operations at Novazyme Pharmaceuticals, Inc. and Manufacturing Director at Centocor, Inc. William J. Fallon received an undergraduate degree from Long Island University and a graduate degree from Northeastern University.
Jean-Pierre Bizzari Currently, Jean-Pierre Bizzari holds the position of President & Director at Synergie Lyon Cancer. Dr. Bizzari is also on the board of 9 other companies. Dr. Bizzari previously was Executive Vice President & Global Head-Oncology at Celgene Corp., Vice President-Clinical Development Oncology at Sanofi-Synthelabo, Inc., Vice President-Clinical Oncology at Rh�0�1�0�7ne-Poulenc, Inc., Vice President-Clinical Oncology Development at Sanofi-Aventis Pharmaceuticals and Head-Oncology at Institut de Recherches Internationales Servier. Dr. Bizzari received a graduate degree and a doctorate from the University of Nice Sophia Antipolis.
Michael J. LaBarre Michael J. LaBarre is VP-Product Development & Regulatory Affairs at Halozyme Therapeutics, Inc. In the past he occupied the position of Director-Analytical & Protein Biochemistry at Biogen, Inc. and Vice President-Product Development at Paramount BioSciences LLC. Dr. LaBarre received an undergraduate degree from The University of Southampton and a doctorate from the University of Arizona.
Renee P. Tannenbaum Renee P. Tannenbaum is on the board of Zogenix, Inc. and Vice President-Global Alliances at Halozyme, Inc. In her past career Dr. Tannenbaum was President for Myrtle Potter & Co. LLC, Head-Global Customer Excellence at AbbVie, Inc., Chief Commercial Officer & Executive VP at Elan Pharmaceuticals, Inc. and Professor at the University of the Sciences in Philadelphia. She received an undergraduate degree and a doctorate from the University of Connecticut, an MBA from Temple University (Pennsylvania) and a doctorate from Philadelphia College of Pharmacy.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
Jean-Pierre Bizzari Currently, Jean-Pierre Bizzari holds the position of President & Director at Synergie Lyon Cancer. Dr. Bizzari is also on the board of 9 other companies. Dr. Bizzari previously was Executive Vice President & Global Head-Oncology at Celgene Corp., Vice President-Clinical Development Oncology at Sanofi-Synthelabo, Inc., Vice President-Clinical Oncology at Rh�0�1�0�7ne-Poulenc, Inc., Vice President-Clinical Oncology Development at Sanofi-Aventis Pharmaceuticals and Head-Oncology at Institut de Recherches Internationales Servier. Dr. Bizzari received a graduate degree and a doctorate from the University of Nice Sophia Antipolis.
Albert S. Kildani Presently, Albert S. Kildani is VP-Investor Relations & Corporate Communications at Halozyme Therapeutics, Inc. Mr. Kildani is also Member of National Investor Relations Institute. In his past career Mr. Kildani held the position of VP-Investor Relations & Business Development at Vital Therapies, Inc., Senior Director-Investor Relations at Hologic, Inc. and Senior Director-Investor Relations at Gen-Probe, Inc. (a subsidiary of Hologic, Inc.) and Managing Director at Global Hunter Securities LLC. Albert S. Kildani received an undergraduate degree from Boston College.
Michael E. Paolucci Michael E. Paolucci is on the board of Orthofix Medical, Inc. and Chief Human Resources Officer & Vice President at Halozyme Therapeutics, Inc. In the past he was Executive Vice President-Global Human Resources at NuVasive, Inc., Partner at Towers Perrin, Inc., Head-Human Resources of Hewlett Packard Enterprise BV and Chief Human Resources Officer & Executive VP of CareFusion Corp. Mr. Paolucci received an undergraduate degree from The Ohio State University.
Harry J. Leonhardt Presently, Harry J. Leonhardt occupies the position of Secretary, Senior VP & General Counsel at Halozyme Therapeutics, Inc. He is also on the board of BIOCOM. Mr. Leonhardt previously was Secretary, Senior Vice President & General Counsel at Ngen, Inc., Chief Litigation Counsel at Allergan, Inc., Attorney at Lyon & Lyon, Inc., Secretary, Executive VP & General Counsel of Genoptix, Inc., Secretary, Senior VP-Legal & Compliance at Amylin Pharmaceuticals, Inc. and Secretary, Senior Vice President & General Counsel at Senomyx, Inc. Harry J. Leonhardt received an undergraduate degree from the University of the Sciences in Philadelphia and a graduate degree from the University of Southern California.
Laurie D. Stelzer Presently, Laurie D. Stelzer is Chief Financial Officer & Senior Vice President at Halozyme Therapeutics, Inc. Ms. Stelzer is also on the board of Surface Oncology, Inc. In her past career she was Treasurer & Head-Global Accounting at Amgen, Inc. and Senior VP-Finance & Head-Investor Relations at Shire, Inc. Ms. Stelzer received an MBA from UCLA Anderson School of Management and an undergraduate degree from Arizona State University.
Alison A. Armour Currently, Alison A. Armour is Senior Vice President-Research & Development at Halozyme Therapeutics, Inc. Dr. Armour is also Member of Royal College of Physicians & Surgeons of Glasgow. In the past Dr. Armour was Vice President-Oncology at GlaxoSmithKline Plc, Vice President-Oncology at Novartis AG and Chief Medical Officer for Endocyte, Inc. (a subsidiary of Novartis AG) and Director-Global Medical Science at AstraZeneca Plc. Dr. Armour received an undergraduate degree, a graduate degree and a doctorate from the University of Glasgow.
Ed Gemo Currently, Ed Gemo is Chief Information & Security Officer, VP at Halozyme Therapeutics, Inc. He previously occupied the position of Chief Information Officer & Senior Vice President of InterMune, Inc. and Chief Information Officer & Vice President of Onyx Pharmaceuticals, Inc. Mr. Gemo received an undergraduate degree from Brooklyn College and an MBA from Pace University.
Bernadette M. Connaughton Bernadette M. Connaughton is on the board of Halozyme Therapeutics, Inc., Visterra, Inc. and Zealand Pharma A. She previously was Head-European Markets at Bristol-Myers Squibb Co. She received an undergraduate degree from The Johns Hopkins University and an MBA from the University of Pennsylvania.
Kristina Vlaovic Kristina Vlaovic holds the position of Vice President-Regulatory & Safety at Halozyme Therapeutics, Inc. In her past career she held the position of Head-Global Regulatory at Genentech, Inc. Ms. Vlaovic received an undergraduate degree and a graduate degree from the University of Michigan.
Homa Yeganegi Currently, Homa Yeganegi holds the position of Senior Vice President-Global PEGPH20 Program Lead at Halozyme Therapeutics, Inc. Ms. Yeganegi received an undergraduate degree from the University of Tehran and a graduate degree from The University of Western Australia.
Dimitrios Chondros Dimitrios Chondros occupies the position of Chief Medical Officer & Senior Vice President at Halozyme Therapeutics, Inc. In his past career he occupied the position of Medical Director at Cell Genesys, Inc. and Member-Antiangiogenesis at Genentech, Inc. He received a doctorate from the University of Zurich.
Benjamin Joseph Hickey Benjamin Joseph Hickey is on the board of Bristol-Myers Squibb Pharmaceuticals Ltd. and Bristol Myers Squibb Holdings 2002 Ltd. and Chief Commercial Officer & Senior Vice President at Halozyme Therapeutics, Inc. Mr. Hickey received an undergraduate degree and an MBA from St. John's University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐